CDC-RFA-PS-24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments
Closed
This grant is closed. A newer notice from the same program is forecast: Demonstration Projects for Whole-Person Health Models for Women Living with HIV in the South (CDC-RFA-PS-27-0061). Status: Expected deadline March 15, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2024.
Centers for Disease Control - NCHHSTP offered grants to state and local governments. It expected to make about 60 awards worth $2.9 billion in total. Applications closed on April 29, 2024.
From the official notice on Grants.gov, last changed February 9, 2024. Checked November 7, 2026.
- Total funding$2.9 billion
- Expected awards60
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 9, 2024 |
|---|---|
| Deadline | April 29, 2024 |
| Archived by Grants.gov | May 9, 2024 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- County governments
- City or township governments
- Special district governments
See funding tables for list of eligible health department jurisdictions for core and EHE funding. Additionally, a fiduciary entity may request funding on behalf of the health department, as evidence by a letter or memorandum of agreement (MOA) with the health department. If a MOA is not provided by the health department and the identified fiduciary or bona fide agent, CDC will consider an alternative funding agreement for the provision of HIV prevention funding resources to that health department jurisdiction.
Is this a realistic fit?
- Most of the program's money (97% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to implement a comprehensive HIV prevention and surveillance program to prevent new HIV infections and improve the health of peoples with HIV. The NOFO aligns with CDC’s Division of HIV Prevention (DHP) strategic focus areas to bolster community engagement, health equity, syndemic and whole-person approaches to HIV prevention. Applicants will have the opportunity to build their proposed HIV prevention and surveillance program by identifying and implementing activities within the jurisdiction, based on need and resources, to reach the stated goal(s) for each strategy. This NOFO allows for flexibility while ensuring that funding resources are reaching the geographic areas with the highest HIV burden and greatest need. The NOFO priorities are to increase knowledge of HIV status, reduce HIV transmission, prevent new HIV infections, improve linkage to care and viral suppression and maintain elimination of perinatal transmission, with populations. The NOFO aims to attain accurate, complete, and timely surveillance and program data for public health action and strengthen cluster and outbreak response efforts to improve services for people in networks experiencing rapid transmission. Optional activities supporting surveillance, prevention, demonstration project and data modernization initiatives may be requested per availability of funding. The integration of core prevention, surveillance, and Ending the HIV Epidemic (EHE) funding resources allows each jurisdiction to align resources to better match the geographic burden of HIV infections within their jurisdictions, to maximize the impact of federal HIV prevention funding and to improve HIV data collection and use for public health action.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before
From fiscal 2021 to 2025, HIV Prevention and Surveillance Activities-Health Department Based (93.940) awarded $1.8 billion across 463 grant awards, an average of $3.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 9 | $183 million |
| City of New York | New York | 8 | $147 million |
| California Department of Public Health | California | 7 | $119 million |
| Department of State Health Services | Texas | 7 | $92.7 million |
| County of Los Angeles | California | 9 | $88.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0061, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS-24-0047 still open?
No. It closed on April 29, 2024. A newer notice is forecast: CDC-RFA-PS-27-0061, expected deadline March 15, 2027.
Who can apply for High-Impact HIV Prevention and Surveillance Programs for Health Departments?
Centers for Disease Control - NCHHSTP accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for High-Impact HIV Prevention and Surveillance Programs for Health Departments?
Closed April 29, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $2.9 billion in total across about 60 awards.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before?
The largest recipients over five fiscal years were Florida Department of Health, City of New York, California Department of Public Health. The program made 463 awards worth $1.8 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)